Established in 1993 and headquartered in Beihai, China, Galaxy Biomedical Investment Co., Ltd. is a diversified enterprise with significant operations across three key sectors: electrical transmission and distribution, electronic information, and biopharmaceuticals. Within its electrical transmission and distribution segment, the company manufactures and supplies a range of transformer solutions, including power, rectifier, and specialized transformers. These critical components serve diverse industrial applications such as metal smelting, electrochemical processes, and power grid infrastructure. The electronic information division specializes in the production and sale of a broad spectrum of electronic components. Its offerings encompass displacement sensors, brake resistance boxes, radio frequency (RF) components, resistors, and potentiometers. These sophisticated parts are integral to a wide array of high-tech industries, including aviation, aerospace, defense, marine applications, artificial intelligence (AI), new energy systems, rail transportation, telecommunications, smart grids, and precision instrumentation. Galaxy Biomedical also maintains a significant presence in the biopharmaceutical sector. Here, its product portfolio includes animal health products, alongside cutting-edge monoclonal antibody and targeted therapies, as well as treatments for cancer and various other medical conditions. Beyond pharmaceuticals, the company supplies essential laboratory equipment and provides advanced research and development services. These services span Contract Research Organization (CRO) support, CAR-T and stem cell technology development, malignant cancer immune cell technologies, and genetic testing. Furthermore, the company engages in the international export of its diverse product lines. Historically, the enterprise was known as Beihai Yinhe Industry Investment Co., Ltd. before officially adopting its current name, Galaxy Biomedical Investment Co., Ltd., in October 2015.